Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03996850 · ClinicalTrials.gov registry record
SPECT/CT for the Characterization of Renal Masses
A clinical trial of Kidney Neoplasm and Renal Mass, sponsored by Jonsson Comprehensive Cancer Center.
- Active
- Registry status
- 102
- Enrollment target
- 1
- Study location
NCT03996850: Active study of Kidney Neoplasm and Renal Mass, sponsored by Jonsson Comprehensive Cancer Center.
NCT03996850 is a study of Kidney Neoplasm and Renal Mass that is active but no longer recruiting, run by Jonsson Comprehensive Cancer Center. The registered enrollment target is 102 participants, below the 192-participant average among 4 other Kidney Neoplasm trials with a reported enrollment target (47% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03996850, a study of Kidney Neoplasm and Renal Mass, is active but no longer recruiting, sponsored by Jonsson Comprehensive Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- 102 participants
- Enrollment target
- 1
- Study location
Study Summary
This trial studies how well technetium Tc-99m sestamibi single-photon emission computed tomography/computed tomography (SPECT/CT) works on clinical decision making in patients with kidney tumors. Diagnostic procedures, such as technetium Tc-99m sestamibi SPECT/CT may be a less invasive way to check for kidney tumors.
Primary Outcome
Assessed with post-test, physician counseling.
Conditions Studied
Interventions
- PROCEDURE Computed Tomography
- OTHER Questionnaire Administration
- PROCEDURE Single Photon Emission Computed Tomography
- RADIATION Technetium Tc-99m Sestamibi
Study Locations (1)
California
- UCLA / Jonsson Comprehensive Cancer Center - Los Angeles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 102 participants |
| Start Date | 2018-12-07 |
| Est. Completion | 2027-12-31 |
What the registry record for NCT03996850 still lists
NCT03996850 is an observational study that tracks outcomes without assigning an intervention. The registered 102 participants enrollment target is mid-sized for trials with a published cap, below the 192-participant average among 4 other Kidney Neoplasm trials with a reported enrollment target (47% lower).
The record links to 2 conditions, with Kidney Neoplasm appearing as the primary indexed condition, and to 4 interventions - of which Computed Tomography is the first listed.
NCT03996850 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT03996850 about?
NCT03996850 is a clinical study titled "SPECT/CT for the Characterization of Renal Masses". This trial studies how well technetium Tc-99m sestamibi single-photon emission computed tomography/computed tomography (SPECT/CT) works on clinical decision making in patients with kidney tumors. Diagnostic procedures, such as technetium Tc-99m sestamibi SPECT/CT may be a less invasive way to check ...
What is the current status of trial NCT03996850?
This trial is currently active not recruiting. The enrollment target is 102 participants. The study started on 2018-12-07. Estimated completion is 2027-12-31.
What conditions does trial NCT03996850 study?
This clinical trial studies the following conditions: Kidney Neoplasm, Renal Mass.
What interventions are being tested in trial NCT03996850?
The interventions under investigation include: Computed Tomography (PROCEDURE), Questionnaire Administration (OTHER), Single Photon Emission Computed Tomography (PROCEDURE), Technetium Tc-99m Sestamibi (RADIATION).
Who is sponsoring clinical trial NCT03996850?
This trial is sponsored by Jonsson Comprehensive Cancer Center, which has 321 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03996850 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Kidney Neoplasm
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
The Delayed Intervention and Surveillance for Small Renal Masses (DISSRM) Registry
RECRUITING
-
Pre-NEOSHIFT-RCC: Neoadjuvant HIF-Inhibitor Immunotherapy in RCC
RECRUITING · Phase 2
-
Hyperpolarized 13C Pyruvate MRI Scan in Predicting Tumor Aggressiveness in Patients With Renal Tumors
ACTIVE NOT RECRUITING · Phase 2
-
A Phase I Study of Infusional Chemotherapy With the P-Glycoprotein Antagonist PSC 833
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03704662 · 102 participants · NA
Preoperative Fractionated Radiation Therapy Versus Stereotactic Body Radiation Therapy for Resectable or Borderline Resectable, or Locally Advanced Type A Pancreatic Adenocarcinoma
- NCT04174742 · 102 participants
Self Reported Pain in Women While Undergoing Treatment for Non-metastatic Breast Cancer
- NCT04275362 · 102 participants
Gait Analysis of a Lateral-Pivot Design Total Knee Replacement
- NCT04541082 · 102 participants · Phase 1
Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI